December 12, 2024 20:30 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
UP teenager kills mother, lives with body for 5 days | At least six people including a child killed in Tamil Nadu hospital fire | Amid Atul Subhash row, SC says mere harassment is not enough to prove abetment to suicide | India's D Gukesh becomes youngest ever world champion in chess | Devendra Fadnavis meets PM Modi amid suspense over Maharashtra portfolio allocation | Congress wants to deviate the issue of Sonia Gandhi-George Soros link: JP Nadda | Bengaluru techie suicide: Atul Subhash's family demanded Rs. 10 lakh as dowry leading to my father's death, claims estranged wife | Syria rebels torch tomb of ousted president Bashar al-Assad's father | Donald Trump vows to eliminate birthright citizenship after taking charge | No alliance with Congress in Delhi polls: AAP chief Arvind Kejriwal
Moderna

Moderna to apply for emergency authorisation in US and Europe after Covid vaccine shows 100 pc efficacy iagainst severe cases

| @indiablooms | Dec 01, 2020, at 04:43 am

Washington/IBNS: Drug manufacturer Moderna has said after full results of a late stage study showed its Covid-19 vaccine has 94.1% effectiveness and no serious safety concerns, it has decided to apply for US and European emergency authorization on Monday, said a Reuters report.

The company also reported that the vaccine showed consistent efficacy across gender, race, ethnicity and age demographics and proved 100 per cent efficient in protecting against severe cases of the disease that has so far claimed 1.5 million people across the globe, said the report.

Earlier, Pfizer and BioNTech, which had a 95% efficacy rate in trials, received emergency use authorization in the US this year.

According to the report, out of the 196 volunteers who contracted COVID-19 in the trial with more than 30,000 people, 185 were administered a placebo while 11 were given the vaccine.

Moderna said it had 30 severe cases, all of whom were in the placebo group, indicating 100% effectiveness of the vaccine in preventing severe cases.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.